The Walt Disney Company (NYSE: DIS)

Rodiano Bonacci
Novembre 18, 2017

The Credit Agricole S A holds 1.66 million shares with $176.32 million value, up from 1.40 million last quarter. Walt Disney Co now has $159.97B valuation. The stock decreased 0.09% or $0.09 during the last trading session, reaching $103.6. 7,500,834 shares of the company traded hands, compared to its average volume of 7,191,291.

More notable recent Walt Disney Co (NYSE:DIS) news were published by: Investorplace.com which released: "Walt Disney Co Has More Buyout Options Than You Think" on November 08, 2017, also Seekingalpha.com with their article: "Disney - Positioned Very Well To Deliver Growth" published on November 15, 2017, Latimes.com published: "Disney's profit disappoints as TV unit struggles" on November 09, 2017. It has underperformed by 7.44% the S&P500. On November 10 Jefferies Group LLC left the stock rating at "Hold" with a current price target of $103.77. Therefore 50% are positive. It was reported on Nov, 17 by Finviz.com. The firm earned "Hold" rating on Thursday, January 19 by Beaufort Securities. Bank of America maintained Walt Disney Co (NYSE:DIS) rating on Friday, June 23. Oppenheimer initiated it with "Outperform" rating and $30 target in Tuesday, October 20 report. As per Friday, August 11, the company rating was maintained by Barclays Capital. The firm has "Buy" rating given on Monday, April 18 by Panmure Gordon.

Traders have different rules for what constitutes liquidity and a good guide is the volume of trades and volume of shares that are traded each day. Alphatec Holdings Inc (NASDAQ:ATEC) has declined 6.76% since November 17, 2016 and is downtrending. It has underperformed by 17.03% the S&P500. The Company's product candidates from its Live, Attenuated, Double-Deleted Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are created to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. The firm attains price to earnings ratio of 92.77 and its current ratio stands at 0.90. The Company's LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers.

Investors sentiment increased to 1.09 in Q2 2017. Its up 0.17, from 0.92 in 2017Q1. However, the institutional investors are observed to own 63.50% of the total shares. First Capital Advisors Group LLC. raised its stake in Walt Disney Company (The) by 0.4% in the second quarter. During last 3 month period, 0.35% of total institutional ownership has changed in the company shares. They expect $0.55 EPS, down 6.78% or $0.04 from last year's $0.59 per share. First Commonwealth Pa has 17,146 shares for 2.01% of their portfolio. Mirador Cap Prns LP holds 2,900 shares. Neuberger Berman Grp Lc accumulated 1.18M shares or 0.16% of the stock. Central National Bank And Trust Commerce holds 1.44% of its portfolio in Walt Disney Co (NYSE:DIS) for 52,212 shares. It is 0.00% or $0 reaching $3.7 per share. Monroe Fincl Bank Mi holds 0.02% in Walt Disney Co (NYSE:DIS) or 600 shares. Usa Portformulas has invested 0.69% in Walt Disney Co (NYSE:DIS). John G Ullman & Assoc Incorporated has invested 0.08% of its portfolio in Walt Disney Co (NYSE:DIS). About 9,380 shares traded. 26,218 are held by Counselors. Ycg Limited Co holds 1.3% or 46,983 shares in its portfolio.

Truenorth Inc, Kansas-based fund reported 10,584 shares. November 10 investment analysts at B. Riley made no change to the stock rating of "Hold" projecting a price of $101.00. Therefore 53% are positive.

In terms of performance, shares of The Walt Disney Company (NYSE:DIS) are -0.59% since the start of 2016. Pivotal Research downgraded Walt Disney Co (NYSE:DIS) rating on Thursday, January 12. Barclays Capital has "Equal-Weight" rating and $98 target. The firm earned "Underperform" rating on Monday, May 15 by BMO Capital Markets. The stock of Walt Disney Co (NYSE:DIS) earned "Neutral" rating by Macquarie Research on Wednesday, May 17. S&P Research has "Buy" rating and $122 target. RBC Capital Markets maintained the stock with "Buy" rating in Thursday, July 13 report. The rating was maintained by KeyBanc Capital Markets with "Overweight" on Wednesday, January 11. As per Thursday, September 29, the company rating was maintained by UBS. On Friday, July 28 the stock rating was downgraded by William Blair to "Market Perform". (The) raised the price target on November 10 changing the price objective from $115.00 to $120.00 with a rating of "Buy".

Daiwa Securities Group Inc, which manages about $15.47 billion US Long portfolio, decreased its stake in Intuitive Surgical (NASDAQ:ISRG) by 2,190 shares to 2,390 shares, valued at $2.24M in 2017Q2, according to the filing. It also upped Vanguard (VWO) stake by 242,033 shares and now owns 327,032 shares. Johnson & Johnson (NYSE:JNJ) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE